Riccardo DANIELLI 

PhD Program years: 2011 - 2014

1. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
   Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M.
   Cancer Immunol Immunother. 2012 Jan
   
   2. Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.
   Danielli R, Fonsatti E, Calabrò L, Giacomo AM, Maio M.
   Ann N Y Acad Sci. 2012 Oct
   
   3. Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides.
   Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L.
   Clin Cancer Res. 2012 Dec 1
   
   

        1. A phase II study with the anti-CTLA-4 mAb Tremelimumab in chemotherapy-resistant advanced malignant mesothelioma                (MM): safety, tolerability, clinical and immunologic activity (EUDRACT-2008-005171-95)
        Luana Calabrò, Anna Maria Di Giacomo, Aldo Morra, Ornella Cutaia, Riccardo Danielli, Ester Fonsatti, Maresa Altomonte,                  Ramy Ibrahim, Alessandra Di Pietro, Shengyan Hong, Luciano Mutti, Michele Maio

       2. Long term survival and immunological correlates in metastatic melanoma treated with ipilimumab at 10 mgs within an                    expanded access program
        A.M. Di Giacomo, L. Calabrò, Danielli I. Pesce E. Fonsatti E. Bertocci D. Giannarelli M. Biagioli M. Altomonte M. Maio ESMO                2012

---